SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: September 23, 1998
Date of earliest event reported: September 10, 1998
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware 1-3619 13-5315170
(State or other (Commission File (I.R.S. Employer
jurisdiction of Number) Identification No.)
incorporation)
235 East 42nd Street
New York, New York 10017
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(212) 573-2323
Item 2. Acquisition or Disposition of Assets
The sale of the Schneider Worldwide business -- a part of
Pfizer Inc.'s Medical Technology Group -- to Boston Scientific
Corporation (BSX) for $2.1 billion in cash, closed on September
10, 1998. The sale was a negotiated, arms-length transaction.
Based in Bulach -- near Zurich, Switzerland -- Schneider
manufactures and sells stents for a variety of applications,
angioplasty devices and accessories. In addition to its global
headquarters in Bulach, Schneider maintains facilities in
Plymouth, Minnesota; Glens Falls, New York; Aguadilla, Puerto
Rico; Miami, Florida; and Tullamore, Ireland. In 1997, Schneider
reported sales of approximately $330 million.
SIGNATURE
Under the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its
behalf by the authorized undersigned.
PFIZER INC.
By: /s/ TERENCE J. GALLAGHER
.............................
Name: Terence J. Gallagher
Title: Vice President-
Corporate Governance
Dated: September 23, 1998
